Framingham-based Alira Health announced this week that it has raised $58 million to accelerate the delivery of tech-enabled healthcare solutions.
Founded in 1999, Alira Health advises pharmaceutical, biotech and medical technology clients around a range of topics, including product development and regulatory issues. Its consultants can also guide clients through the entire clinical trial process.
Alira Health also offers a suite of technology solutions for the clinical trial process. Its Health Storylines platform, for example, allows participants of decentralized clinical trials to keep track of their medication schedule and track any symptoms they might experience.
In May, the company acquired RedCrow, an equity crowdfunding platform for healthcare startups.
Alira Health has more than 700 employees around the world, and it expects to reach more than 900 employees by 2024. More than 70 employees are based in the Boston area. In addition to its headquarters office in Framingham, the company also has offices in the Cambridge Innovation Center at Kendall Square.
Alira Health’s latest capital injection brings the company’s total funds raised to $133 million, which includes a $40 million round in 2022 and a $35 million round in 2021. Both of those rounds were led by Creadev.
Alira Health is currently focused on potential opportunities brought about by the 21st Century Cures Act enacted in 2016 — specifically a provision that allows patients to access their own electronic health information and prevents other entities from blocking that information.
“With the Cures Act empowering patients to access their own data, Alira Health is well positioned with a significant tailwind in our favor as we have been preparing for this major paradigm shift for years,” Alira Health co-founder and CEO Gabriele Brambilla said in a statement. “We are executing on our winning strategy to become a patient-centric solutions provider enabled by innovative technologies that will collect clinical and real-world data directly from patients, powerfully informing the development of new drugs and devices. Our investors are excited to share our vision and support us in our mission to positively impact the life of every patient.”
